Case Studies

Challenge: A newly-formed US biotech company has acquired the intellectual property and assets of a legacy cancer vaccine company that had ceased trading several years ago following disappointing...

Challenge: A biotech company with an AI-approach to developing new TCRs for immunotherapy asked Alacrita to assist in preparations for the J.P. Morgan Healthcare conference.

Challenge: A contract development and manufacturing organization (CDMO) was in negotiations to acquire two manufacturing sites from other companies. Under normal circumstances, the client would have...

Challenge: For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three...

Challenge: A biotechnology startup had entered a major licensing deal with Big Pharma and was able to fund operations via the upfront payment rather than needing to raise a Series A. This introduced...

Challenge: A European investment trust was considering an investment in a Phase 3 gene therapy opportunity targeting a niche oncology indication. Owing to the circumstances of the deal, they had less...

Challenge: A biotech company developing immunomodulatory therapies asked Alacrita to assess the possible applications of its lead product, particularly in the context of improving the efficacy of...

Challenge On behalf of an established Alacrita client, a publicly traded clinical stage biotechnology company with a cell therapy platform technology, we assessed the potential of a novel...

Challenge A clinical-stage biotech company had an ongoing Phase 1 program exploring a combination therapy in multiple cancer types. The company wished to validate the addition of cholangiocarcinoma...

Challenge A UK-based oncology drug development company sought to understand the potential value of a small molecule product in metastatic breast cancer (MBC). Alacrita was commissioned to produce an...

Challenge A clinical stage microbiome company developing a microbiome therapeutic for the treatment of recurrent C. Difficile infection (rCDI) was looking to identify promising opportunities for new...

Challenge An early-stage, venture-backed, private biotechnology company developing a novel multi-gene therapy approach to addressing chronic, age-related diseases requested an opportunity mapping...